Philadelphia Pennsylvania Lawyers at Monheit Law

 

Swiss drug giant Novartis is faced with class action and individual lawsuits over Zelnorm. It is likely that there could also be a shareholder lawsuit as well. The company reduced the 2007 sales forecast for IBS drug Zelnorm. Sales were halted by the FDA request since it appears that the treatment is linked to a ten-fold increase of risk of heart attacks and strokes.

Zelnorm (tegaserod) maker has said that "we continue to believe that Zelnorm provides important benefits for appropriate patients." Novartis is taking the position that the rate of cardiovascular ischemic events seen in Zelnorm-treated patients in controlled trials "corresponds approximately with the expected rates for such events in the general population," adding that "a small (but not statistically significant) imbalance in cases of angina pectoris" was included in the US label when the drug was approved in 2002.

The FDA however believes the "risk of very serious harm to patients who have this non-life-threatening condition" makes "this action necessary."

Library of Zelnorm Articles:

 


 

First Name*:
Last Name*:
E-mail*:
Phone*:  -
Address:
 
City:
State:
Zip:
Dates you took Zelnorm:
From: 
To: 

Injuries Caused by Zelnorm:

 

Heart attack

Death

Other heart problems

Atrial Fibrillation

Irregular Heart Beat

Unstable Angina

Ventricular Fibrillation

Stroke
Meningitis

Arrhythmia

Heart Murmur

Ischemic event
Ventricular Tachycardia

 

Date of Injury/Diagnosis:

Symptoms (check all that apply):

Chest Pain
Weakness
Difficulty Breathing
Shortness of Breath
 

Why were you given Zelnorm?:

Chronic Constipation
IBS (Irritable Bowel Syndrome)

Other

 

Please describe what happened?:

 

 

Philadelphia Lawyers - Pennsylvania Lawsuits at Monheit Law

Law Offices of Michael Monheit 1368 Barrowdale Road  Rydal, PA  19046
Call Us Toll Free: 866-761-1385  P: 215-840-6573  E: Michael@Monheit.com